These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

274 related articles for article (PubMed ID: 37723058)

  • 1. [NAFLD renaming to MAFLD, MASLD: background, similarities, differences, and countermeasures].
    Fan JG; Li XY
    Zhonghua Gan Zang Bing Za Zhi; 2023 Aug; 31(8):789-792. PubMed ID: 37723058
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of nomenclature as metabolic associated steatotic liver disease on steatotic liver disease prevalence and screening: a prospective population survey in Asians.
    Wu T; Ye J; Mo S; Ye M; Li X; Li Q; Wang W; Zheng Q; Luo K; Zhang Y; Tu S; Che D; Gong R; Chen X; Miu R; Shao C; Sun Y; Zhong B
    J Gastroenterol Hepatol; 2024 Aug; 39(8):1636-1647. PubMed ID: 38695344
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparing similarities and differences between NAFLD, MAFLD, and MASLD in the general U.S. population.
    Zou H; Ma X; Pan W; Xie Y
    Front Nutr; 2024; 11():1411802. PubMed ID: 39040926
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Differences in the prevalence of NAFLD, MAFLD, and MASLD according to changes in the nomenclature in a health check-up using MRI-derived proton density fat fraction.
    Park HJ; Lee S; Lee JS
    Abdom Radiol (NY); 2024 Sep; 49(9):3036-3044. PubMed ID: 38587630
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Steatotic liver disease, MASLD and risk of chronic kidney disease.
    Bilson J; Mantovani A; Byrne CD; Targher G
    Diabetes Metab; 2024 Jan; 50(1):101506. PubMed ID: 38141808
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nonalcoholic fatty liver disease versus metabolic-associated fatty liver disease: Prevalence, outcomes and implications of a change in name.
    Ng CH; Huang DQ; Nguyen MH
    Clin Mol Hepatol; 2022 Oct; 28(4):790-801. PubMed ID: 35545437
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Breaking new ground: MASLD vs. MAFLD-which holds the key for risk stratification?
    Ramírez-Mejía MM; Jiménez-Gutiérrez C; Eslam M; George J; Méndez-Sánchez N
    Hepatol Int; 2024 Feb; 18(1):168-178. PubMed ID: 38127259
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Metabolic dysfunction-associated steatotic liver disease: Evolution of the final terminology.
    Portincasa P; Baffy G
    Eur J Intern Med; 2024 Jun; 124():35-39. PubMed ID: 38653634
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of NAFLD, MAFLD and MASLD characteristics and mortality outcomes in United States adults.
    Song R; Li Z; Zhang Y; Tan J; Chen Z
    Liver Int; 2024 Apr; 44(4):1051-1060. PubMed ID: 38293788
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Analysis of non-alcoholic fatty liver disease differences from metabolic dysfunction-associated fatty liver disease based on clinical features].
    Liu YX; Guo F; Niu LN; Zhang B; Dou J; Xu Q; Ning ZH; Wang XZ
    Zhonghua Gan Zang Bing Za Zhi; 2024 Apr; 32(4):346-353. PubMed ID: 38733190
    [No Abstract]   [Full Text] [Related]  

  • 11. Non-invasive Scores and Serum Biomarkers for Fatty Liver in the Era of Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD): A Comprehensive Review From NAFLD to MAFLD and MASLD.
    Abdelhameed F; Kite C; Lagojda L; Dallaway A; Chatha KK; Chaggar SS; Dalamaga M; Kassi E; Kyrou I; Randeva HS
    Curr Obes Rep; 2024 Sep; 13(3):510-531. PubMed ID: 38809396
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Effect of the nomenclature of non-alcoholic fatty liver disease on diagnosis and treatment of fatty liver disease concomitant with other liver diseases].
    Chen L; Jiang LN; Zhao JM
    Zhonghua Gan Zang Bing Za Zhi; 2023 Aug; 31(8):805-809. PubMed ID: 37723061
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Editorial: International Consensus Recommendations to Replace the Terminology of Non-Alcoholic Fatty Liver Disease (NAFLD) with Metabolic-Associated Fatty Liver Disease (MAFLD).
    Méndez-Sánchez N; Díaz-Orozco LE
    Med Sci Monit; 2021 Jul; 27():e933860. PubMed ID: 34248137
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prevalence and characteristics of MAFLD in Chinese adults aged 40 years or older: A community-based study.
    Zeng J; Qin L; Jin Q; Yang RX; Ning G; Su Q; Yang Z; Fan JG
    Hepatobiliary Pancreat Dis Int; 2022 Apr; 21(2):154-161. PubMed ID: 35153138
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Global survey of stigma among physicians and patients with nonalcoholic fatty liver disease.
    Younossi ZM; Alqahtani SA; Alswat K; Yilmaz Y; Keklikkiran C; Funuyet-Salas J; Romero-Gómez M; Fan JG; Zheng MH; El-Kassas M; Castera L; Liu CJ; Wai-Sun Wong V; Zelber-Sagi S; Allen AM; Lam B; Treeprasertsuk S; Hameed S; Takahashi H; Kawaguchi T; Schattenberg JM; Duseja A; Newsome PN; Francque S; Spearman CW; Castellanos Fernández MI; Burra P; Roberts SK; Chan WK; Arrese M; Silva M; Rinella M; Singal AK; Gordon S; Fuchs M; Alkhouri N; Cusi K; Loomba R; Ranagan J; Eskridge W; Kautz A; Ong JP; Kugelmas M; Eguchi Y; Diago M; Yu ML; Gerber L; Fornaresio L; Nader F; Henry L; Racila A; Golabi P; Stepanova M; Carrieri P; Lazarus JV;
    J Hepatol; 2024 Mar; 80(3):419-430. PubMed ID: 37984709
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative study of MAFLD as a predictor of metabolic disease treatment for NAFLD.
    Imai J; Takashimizu S; Suzuki N; Ohshinden K; Sawamoto K; Mishima Y; Tsuruya K; Arase Y; Yamano M; Kishimoto N; Yamada C; Inoue N; Moriyama K; Baba A; Suzuki H; Kagawa T; Nishizaki Y
    Sci Rep; 2024 Jun; 14(1):13411. PubMed ID: 38862756
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nonalcoholic Fatty Liver Disease Without Metabolic-associated Fatty Liver Disease and the Risk of Metabolic Syndrome.
    Sinn DH; Kang D; Choi SC; Hong YS; Zhao D; Guallar E; Park Y; Cho J; Gwak GY
    Clin Gastroenterol Hepatol; 2023 Jul; 21(7):1873-1880.e1. PubMed ID: 36152895
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nonalcoholic fatty liver disease or metabolic dysfunction-associated fatty liver disease diagnoses and cardiovascular diseases: From epidemiology to drug approaches.
    Dongiovanni P; Paolini E; Corsini A; Sirtori CR; Ruscica M
    Eur J Clin Invest; 2021 Jul; 51(7):e13519. PubMed ID: 33583033
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Deciphering metabolic dysfunction-associated steatotic liver disease: insights from predictive modeling and clustering analysis.
    Mori K; Akiyama Y; Tanaka M; Sato T; Endo K; Hosaka I; Hanawa N; Sakamoto N; Furuhashi M
    J Gastroenterol Hepatol; 2024 Jul; 39(7):1382-1393. PubMed ID: 38629681
    [TBL] [Abstract][Full Text] [Related]  

  • 20. From non-alcoholic fatty liver disease (NAFLD) to steatotic liver disease (SLD): an ongoing journey towards refining the terminology for this prevalent metabolic condition and unmet clinical need.
    Kokkorakis M; Boutari C; Katsiki N; Mantzoros CS
    Metabolism; 2023 Oct; 147():155664. PubMed ID: 37517792
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 14.